Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2)

Higuchi, Katsuhiko; Komori, Shouko; Tanabe, Satoshi; Katada, Chikatoshi; Azuma, Mizutomo; Ishiyama, Hiromichi; Sasaki, Takeshi; Ishido, Kenji; Katada, Natsuya; Hayakawa, Kazushige; Koizumi, Wasaburo

doi:10.1016/j.ijrobp.2014.03.030

Cited by 73 publications

(67 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Higuchi et al reported remarkably good results [8], findings from other institutions have remained unchanged [9][10][11][12][13] (Table 4). …”

Section: Discussionmentioning

confidence: 93%

“…We expected FDG-PET to improve the results by excluding small distant organ metastasis; however, an improvement in results was not achieved. The best results in previous studies were obtained by using concurrent DCF (docetaxel, cisplatin and 5-FU) with radiotherapy in patients with relatively good performance status [8]. Based on acceptable toxicities in the report [8], maybe more aggressive treatment such as that performed by Higuchi et al should be considered for improving treatment results in patients with good performance status.…”

Section: Discussionmentioning

confidence: 97%

“…The best results in previous studies were obtained by using concurrent DCF (docetaxel, cisplatin and 5-FU) with radiotherapy in patients with relatively good performance status [8]. Based on acceptable toxicities in the report [8], maybe more aggressive treatment such as that performed by Higuchi et al should be considered for improving treatment results in patients with good performance status. Because the DCF regimen in the present study was performed in only 5 patients, the superiority of the DCF regimen over other regimens is unknown; therefore, a randomized study is necessary.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although Higuchi et al reported remarkably good results [8], findings from other institutions have remained unchanged [9][10][11][12][13] (Table 4). …”

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

et al. 2015

View full text Add to dashboard Cite

show abstract

“…On the other hand, DCF CRT was originally and uniquely developed as alternate dCRT, especially for ESCC with cT4 or M1 lymph nodes or their counterparts of recurrences since May 2005 [24] . Patients received intravenous infusions of DTX (35 mg/m 2 ) and CDDP (40 mg/m 2 ) on day 1 and a continuous intravenous infusion of 5-FU (400 mg/m 2 ) on days 1-5, every 2 weeks, plus concurrent radiation.…”

Section: Definitive Chemoradiation Therapymentioning

confidence: 99%

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

Yamashita¹,

Hosoda²,

Moriya³

et al. 2017

Oncology

Self Cite

View full text Add to dashboard Cite

Background: Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages remain unclear. The latest prognostic outcomes in clinical Stage (cStage) II/III ESCC with NAC were herein elucidated. Patients and Methods: NAC prior to curative treatment was done in 115 cStage II/III ESCC patients with either cisplatin (CDDP)/5-fluorouracil (5-FU; CF) (n = 41) or docetaxel/CDDP/5-FU (DCF) NAC (n = 74) between 2007 and 2013. Results: (1) Esophagectomy was finally performed in 35 of the 41 CF NAC cases and in 48 of the 74 DCF NAC cases. The preservation rate of the esophagus was higher in the DCF NAC than in the CF NAC (p = 0.018). (2) The overall survival was better in DCF NAC than in CF NAC (p = 0.071), and progression-free survivals were 58.3% with DCF and 30.5% with CF (p = 0.0060). DCF NAC was associated with fewer cases of progression than CF NAC (p = 0.0040), largely due to excellent control of the preoperative disease (p = 0.018) and postoperative lymph node recurrence (p = 0.014). Conclusion: DCF NAC in cStage II/III ESCC could have a great potential to achieve a better prognosis due to suppression of specific progression events with a higher preservation rate of the esophagus.

show abstract

“…Another clinical trials of 5-FU and cisplatin and 60 Gy irradiation for patients including clinical T4 showed that CR rate was 15-33 % and 2-year, 3 year survival rates were 27-46 % and 23-30 %, respectively [7,8,[42][43][44]. Other combination regimen using new drugs (paclitaxel, docetaxel, oxaliplatin, S-1, and cetuximab) with concurrent radiotherapy have been evaluated [46][47][48][49]. Fig.…”

Section: Chemoradiotherapy For Unresectable Locallymentioning

confidence: 99%

Radiation Therapy

Ito¹

2014

Esophageal Squamous Cell Carcinoma

View full text Add to dashboard Cite

Radiotherapy is indicated for the treatment of esophageal cancer both with curative intent and with palliative intent. Concurrent chemoradiotherapy is the standard treatment for patients in good condition who can receive chemotherapy, based on the result of randomized trial that compared chemoradiotherapy with radiotherapy alone. For locally advanced unresectable esophageal cancer, definitive chemoradiotherapy is the standard therapy with potentially curative intent. And for resectable esophageal cancer, definitive chemoradiotherapy is a treatment option in an attempt to preserve the esophagus from favorable results of clinical trials. These results are supported by salvage treatment in cases of residual or recurrent disease after chemoradiotherapy. However high mortality rate of salvage surgery and high incidence of late toxicities after chemoradiotherapy with higher radiation dose are important problems to be solved. Neoadjuvant chemoradiotherapy is standard treatment for locally advanced esophageal cancer in Western countries; however it is investigational in Japan. Combination chemotherapy of new agents and new radiotherapy technique such as intensity-modulated radiation therapy, protonbeam therapy, and heavy-particle radiotherapy have been evaluated in clinical trials to improve the treatment results including efficacy and toxicity.

show abstract

Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2)

Cited by 73 publications

References 26 publications

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

Radiation Therapy

Contact Info

Product

Resources

About